Logo

SYBX

Synlogic, Inc.

SYBX

Synlogic, Inc. • NASDAQ
$1.46 ▼ -11.52% (-0.19)
Market Cap $17.08 M
52w High $1.96
52w Low $0.90
Dividend Yield 0%
P/E -5.62
Volume 145.68K
Outstanding Shares 11.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $826K ▲ $-2.301M ▼ 0% $-0.19 ▼ $-2.301M ▼
Q2-2025 $0 $786K ▼ $-529K ▼ 0% $-0.043 ▼ $-529K ▼
Q1-2025 $0 $858K ▼ $317K ▲ 0% $0.026 ▲ $317K ▼
Q4-2024 $0 $1.776M ▲ $-714K ▼ 0% $-0.06 ▼ $348K ▼
Q3-2024 $0 $748K $-117K 0% $-0.01 $514K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.591M ▼ $16.555M ▼ $6.23M ▲ $10.325M ▼
Q2-2025 $17.027M ▼ $17.37M ▼ $4.777M ▼ $12.593M ▼
Q1-2025 $17.271M ▼ $17.966M ▼ $4.873M ▼ $13.093M ▲
Q4-2024 $18.86M ▼ $19.826M ▼ $7.075M ▼ $12.751M ▼
Q3-2024 $19.389M $20.755M $7.647M $13.108M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.301M ▼ $-1.436M ▼ $0 ▼ $0 $-1.436M ▼ $-1.436M ▼
Q2-2025 $-529K ▼ $-399K ▲ $155K ▲ $0 $-244K ▲ $-399K ▲
Q1-2025 $317K ▲ $-1.601M ▼ $12K ▼ $0 ▼ $-1.589M ▼ $-1.601M ▼
Q4-2024 $-714K ▼ $-568K ▲ $30K ▼ $9K ▲ $-529K ▲ $-568K ▲
Q3-2024 $-117K $-648K $72K $-1K $-577K $-648K

Five-Year Company Overview

Income Statement

Income Statement Synlogic is still a pure research-stage biotech, with essentially no product revenue over the past several years. The income statement is dominated by research and operating costs, which lead to steady losses each year. The size of the loss has been fairly consistent in absolute terms, but the loss per share looks large because the company has done reverse stock splits, which concentrate those losses into a smaller share count. Overall, the business has not yet shown any sign of commercial-scale income; it is entirely dependent on the promise of its pipeline, not on current sales.

Balance Sheet

Balance Sheet The balance sheet is small and has been shrinking. Total assets and shareholder equity peaked a few years ago and have since trended down as losses accumulate. Cash is modest and not growing, suggesting a limited financial cushion. Debt levels are low to negligible, which reduces interest-burden risk but also reflects that the company mainly funds itself through equity rather than borrowing. In simple terms, Synlogic now looks like a very lean organization with constrained resources and a thin capital base, which heightens sensitivity to any funding or clinical setbacks.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing R&D and operating expenses without offsetting revenue. Free cash flow tracks very closely with operating cash flow because capital spending is minimal; this is a people- and lab-driven business, not a capital-intensive one. There are signs that cash burn has eased slightly more recently, but the company is still using cash rather than generating it. That means Synlogic’s ability to continue its programs depends on access to outside capital or partnerships, and its runway will be an important point of uncertainty.

Competitive Edge

Competitive Edge Synlogic’s competitive strength lies in its specialized Synthetic Biotic platform and early mover position in using engineered probiotics as medicines. It has built know-how, tools, and intellectual property that make it hard for a new entrant to quickly copy its approach. Partnerships with larger players like Roche and Ginkgo provide external validation and some added resources. At the same time, Synlogic is tiny compared with the large pharmaceutical and biotech companies it ultimately competes with for patients, partners, talent, and capital. Existing and emerging treatments in its target diseases—from diet-based approaches to enzyme therapies and gene therapies—mean that clinical performance must be clearly compelling to carve out a durable niche.

Innovation and R&D

Innovation and R&D Innovation is the core of Synlogic’s identity. The company is trying to pioneer “living medicines” that act in the gut, with a modular platform that can be reprogrammed for different diseases. Lead programs in conditions like phenylketonuria, homocystinuria, and enteric hyperoxaluria show how the same basic technology can be adapted to break down different harmful metabolites. Everything about the financial profile—persistent losses, negative cash flow, light capital spending—reflects a company pouring resources into R&D rather than commercialization. The upside is the potential for a versatile new class of drugs; the downside is the high scientific, clinical, and regulatory risk that comes with being early in a new field.

Summary

Synlogic is a very early-stage biotech: scientifically ambitious, financially fragile. It has no commercial revenue and runs steady losses as it funds cutting-edge research into engineered probiotic therapies. Its balance sheet and cash flows show a small company that has already consumed a significant portion of its capital base and continues to rely on external funding. On the strategic side, it has a differentiated platform, specialized expertise, and notable collaborations that support a credible scientific story. However, the company’s size, limited resources, and lack of approved products make its future highly dependent on successful clinical results, continued partner support, and access to new capital. This combination of high scientific potential and elevated financial and execution risk is typical of clinical-stage biotech firms but is especially pronounced here given the company’s current scale and cash position.